Castration-resistant prostate cancer: AUA guideline amendment

Michael S. Cookson, William T. Lowrance, Mohammad H Murad, Adam S. Kibel

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. Materials and Methods The original systematic review and meta-analysis of the published literature yielded 303 articles published from 1996 through 2013. This review formed a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. In April 2014, the CRPC guideline underwent amendment based on a second comprehensive literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. Results Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements. Specifically, the addition of Radium-223 was placed in the guidelines related to the treatment of CRPC. Conclusions Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. The newly incorporated evidence-based statements supplement the original guideline published in 2013, which provided guidance for the treatment of men with CRPC. This guideline will be continually updated as new literature emerges in the field.

Original languageEnglish (US)
Pages (from-to)491-499
Number of pages9
JournalJournal of Urology
Volume193
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Castration
Prostatic Neoplasms
Guidelines
Radium
Patient Preference
Expert Testimony
Therapeutics
Meta-Analysis

Keywords

  • prostatic neoplasms
  • radiopharmaceuticals
  • radium

ASJC Scopus subject areas

  • Urology

Cite this

Castration-resistant prostate cancer : AUA guideline amendment. / Cookson, Michael S.; Lowrance, William T.; Murad, Mohammad H; Kibel, Adam S.

In: Journal of Urology, Vol. 193, No. 2, 01.02.2015, p. 491-499.

Research output: Contribution to journalArticle

Cookson, Michael S. ; Lowrance, William T. ; Murad, Mohammad H ; Kibel, Adam S. / Castration-resistant prostate cancer : AUA guideline amendment. In: Journal of Urology. 2015 ; Vol. 193, No. 2. pp. 491-499.
@article{b82ee4db989b4639a0d00208fcc06526,
title = "Castration-resistant prostate cancer: AUA guideline amendment",
abstract = "Purpose The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. Materials and Methods The original systematic review and meta-analysis of the published literature yielded 303 articles published from 1996 through 2013. This review formed a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. In April 2014, the CRPC guideline underwent amendment based on a second comprehensive literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. Results Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements. Specifically, the addition of Radium-223 was placed in the guidelines related to the treatment of CRPC. Conclusions Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. The newly incorporated evidence-based statements supplement the original guideline published in 2013, which provided guidance for the treatment of men with CRPC. This guideline will be continually updated as new literature emerges in the field.",
keywords = "prostatic neoplasms, radiopharmaceuticals, radium",
author = "Cookson, {Michael S.} and Lowrance, {William T.} and Murad, {Mohammad H} and Kibel, {Adam S.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.juro.2014.10.104",
language = "English (US)",
volume = "193",
pages = "491--499",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Castration-resistant prostate cancer

T2 - AUA guideline amendment

AU - Cookson, Michael S.

AU - Lowrance, William T.

AU - Murad, Mohammad H

AU - Kibel, Adam S.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Purpose The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. Materials and Methods The original systematic review and meta-analysis of the published literature yielded 303 articles published from 1996 through 2013. This review formed a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. In April 2014, the CRPC guideline underwent amendment based on a second comprehensive literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. Results Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements. Specifically, the addition of Radium-223 was placed in the guidelines related to the treatment of CRPC. Conclusions Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. The newly incorporated evidence-based statements supplement the original guideline published in 2013, which provided guidance for the treatment of men with CRPC. This guideline will be continually updated as new literature emerges in the field.

AB - Purpose The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. Materials and Methods The original systematic review and meta-analysis of the published literature yielded 303 articles published from 1996 through 2013. This review formed a majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence-based data. In April 2014, the CRPC guideline underwent amendment based on a second comprehensive literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. Results Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements. Specifically, the addition of Radium-223 was placed in the guidelines related to the treatment of CRPC. Conclusions Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. The newly incorporated evidence-based statements supplement the original guideline published in 2013, which provided guidance for the treatment of men with CRPC. This guideline will be continually updated as new literature emerges in the field.

KW - prostatic neoplasms

KW - radiopharmaceuticals

KW - radium

UR - http://www.scopus.com/inward/record.url?scp=84920748709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920748709&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.10.104

DO - 10.1016/j.juro.2014.10.104

M3 - Article

C2 - 25444753

AN - SCOPUS:84920748709

VL - 193

SP - 491

EP - 499

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -